Wells Fargo & Company Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective dropped by analysts at Wells Fargo & Company from $8.00 to $6.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 244.83% from the company’s previous close.

ZNTL has been the subject of a number of other reports. Guggenheim reduced their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. UBS Group reduced their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday. HC Wainwright decreased their target price on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Stock Up 4.8 %

Shares of ZNTL stock opened at $1.74 on Thursday. The firm has a market cap of $124.00 million, a price-to-earnings ratio of -0.70 and a beta of 1.86. Zentalis Pharmaceuticals has a 52-week low of $1.66 and a 52-week high of $18.07. The company’s 50 day moving average is $2.94 and its 200 day moving average is $3.27.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth about $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals in the 3rd quarter worth approximately $37,000. Aigen Investment Management LP purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $41,000. Capstone Investment Advisors LLC acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at approximately $48,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after acquiring an additional 5,333 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.